Drug Trial Radar · NCT05572970
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Agenus Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 10, 2022
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
This is an expanded access study for cancer treatment with balstilimab alone or in combination with zalifrelimab for an intermediate-size participant population. This study addresses the treatment needs of participants who have been previously and specifically treated with balstilimab alone or in combination with zalifrelimab in a clinical study, who have experienced a benefit from this treatment and/or wish to continue treatment, and who are eligible for treatment under this expanded access study.
Conditions
- Cancer
Interventions
BalstilimabDrug
An anti-programmed death 1 (PD-1) monoclonal antibody.
ZalifrelimabDrug
An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Available
Arizona Oncology Associates
Tucson, Arizona · Available
Hoag Gynecologic Oncology
Newport Beach, California · Available
University of California, San Francisco Medical Center
San Francisco, California · Available
The Ohio State University Wexner Medical Center
Columbus, Ohio · Available
Women & Infants Hospital of Rhode Island
Providence, Rhode Island · Available
Texas Oncology
Flower Mound, Texas · Available
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.